Place of incretin mimetics and dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes. Type 2 diabetes is a progressive disease caused by a combination of insulin resistance and -cell dysfunction of pancreas. Recent studies underline the role of the incretin hormones in -cell function and development. Glucagon-like peptide-1 (GLP-1) stimulate the secretion of insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake. Understanding of the role of GLP-1 in insulin and blood glucose regulation has resulted in the development of new groups of agents into the treatment of diabetes - incretin mimetic agonists and dipeptidyl peptidase-4 inhibitors (DPP-4). This review summarizes the place of GLP-1 agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.

Keywords: type 2 diabetes, guidelines and treatment algorithm, incretin defect, glucagon-like-peptide-1 (GLP-1), GLP-1 agonists, DPP-4 inhibitors.